A Survey of “Joint Working” Between thePharmaceutical Industry and the NationalHealth Service in the United KingdomLockwoo...
Upcoming SlideShare
Loading in...5

A survey of joint working between the pharmaceutical industry and the national health service in the United Kingdom


Published on

research poster by IHS Healthcare and Pharma for ISPOR 2012: Joint Working between pharma and NHS in the United Kingdom

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

A survey of joint working between the pharmaceutical industry and the national health service in the United Kingdom

  1. 1. A Survey of “Joint Working” Between thePharmaceutical Industry and the NationalHealth Service in the United KingdomLockwood C, Marinoni G, Ando G (IHS, London, United Kingdom)Introduction Figure 2. Segmentation of NHS joint-working projects by therapeutic area Source: IHS secondary research“Joint-working” between the pharmaceutical industry and the NHShas emerged as a high-profile policy initiative in the UnitedKingdom (UK). Spearheaded by the Department of Health (DH),ABPI, and other stakeholders, this agenda has been influenced bythe NHS quality/productivity drive, which has increasinglyprompted health-service managers to consider external supportas a means to plug the resources gap.ObjectivesThis study sought to characterise the current landscape for Joint- “Other” includes allergy, central nervous system, dermatology, drug addiction, long-term conditions, nephrology, nutrition, ophthalmology,working in the UK by surveying the types of projects being smoking cessation, urology, and vaccinesundertaken by industry and the NHS. In terms of classification, those projects identified uniquely as Service Development initiatives accounted for the largest singleMethods category, at 25% (42 projects) (Table 1). To ascertain whether a correlation between Respiratory and Service DevelopmentThe websites of major pharmaceutical companies, NHS projects was driving this finding, projects were jointly segmentedorganizations, and other stakeholders were consulted to create a by TA and category (the latter on a “double-counting” basis wherelist of joint-working projects documented in the public domain. To there were multiple category assignments). Each TA/categoryqualify as a joint-working project, collaborations had to involve a pairing was then expressed as a percentage of the total numbersustained commitment from industry beyond traditional of projects in that TA. The results indicate that Servicesponsorship. A classification system was then devised to segment Development projects are common across prevalent TAs, and thatprojects. Finally, the resulting database was then analysed to this category does not in fact account for the highest percentageascertain qualitative and basic quantitative insights into the UK of Respiratory projects.joint-working environment. Table 1. Categorisation of NHS joint-working projects Source: IHS secondary researchResults Project category Number (Percentage of total) Service Development 40 (27%)A total of 165 joint-working projects, involving 37 pharmaceutical HCP Education 26 (16%)companies, were identified; of these, 129 (78%) involved a single Service Optimisation 21 (13%)pharmaceutical company and 36 (22%) involved multiple industry Patient Education 17 (10%)partners. Large, multinational, innovator pharmaceutical Screening 14 (8%)companies appear to be the most active industry participants in Capacity Support 15 (9%)Joint-working (Figure 1). Smaller entities tend to enter multi- Guideline Implementation 14 (8%) Guideline Development 12 (7%)company projects, while this breakdown (single/multi-company) Service Audit 11 (7%)varied across the large players (Figure 1). Commissioning Support 11 (7%) Awareness Raising 7 (4%)Figure 1. Number of NHS joint-working projects by pharmaceutical companySource: IHS secondary research Medicines Review 4 (2%) Unidentified 2 (1%) Publication 1 (1%) Conclusions While involvement from the TA perspective tends to align with company portfolios, there is evidence that multi-company projects—often centered broadly on medicines or multiple indications—account for a considerable share of Joint-working, indicating that objectives other than direct market access influence industry strategy in this arena. While the trends observed here will have been influenced by the extent of, and any biases in, individual company disclosure of joint-working projects, it appears that the Respiratory TAThe Respiratory TA dominates UK Joint-working, accounting for dominates the UK joint-working landscape by some margin. Theover a quarter of the identified projects (Figure 2). The majority of dominance of this TA and prevalence of certain others (e.g.,these (39 in total) correspond to chronic obstructive pulmonary Metabolic and Cardiovascular) may, in addition to reflecting thedisease, with five dedicated to asthma and one to both UK disease burden, also relate to the impact of the QOF, anindications. Of those projects pertaining to specific indications or incentive scheme that rewards practitioners for serviceTAs, the companies participating in them hold assets in the achievements across these areas. Projects enabling managers tocorresponding areas as a general rule; however, Multiple TA meet these targets may have helped boost the uptake of theseinitiatives (e.g., medicines review or waste-management initiatives. Existing research suggests that these TA trends areprogrammes) make up 9% of the total identified projects. broadly in alignment with NHS needs, although there may be greater demand for projects centered on LTCs. FOR MORE INFORMATION ABOUT IHS GLOBAL INSIGHT HEALTHCARE & PHARMACEUTICAL SERVICES www.ihs.com/healthcare and www.ihs.com/healthcareblog Please email: gustav.ando@ihs.com for any questions related to this poster